PREDICT trial - a step toward better cancer diagnosis

With funding support from Luminesce Alliance, the cancer PREDisposition In Childhood by Trio sequencing study (PREDICT), assesses the clinical benefit and utility of family-based germline Whole Genome Sequence to identify underlying cancer predisposition.

The PREDICT team recruited more than 200 patients/families in the past 3 years publishing their first protocol paper. View publication here.